珈凯生物
(920165)
| 流通市值：3.26亿 | | | 总市值：16.39亿 |
| 流通股本：960.50万 | | | 总股本：4827.44万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 151,131,040.55 | 74,949,661.97 | 262,659,452.34 | 194,811,084.95 |
| 营业收入 | 151,131,040.55 | 74,949,661.97 | 262,659,452.34 | 194,811,084.95 |
| 二、营业总成本 | 108,318,089.38 | 52,787,232.97 | 191,607,475.3 | 142,492,352.08 |
| 营业成本 | 53,631,747.48 | 25,952,836.19 | 94,591,916.25 | 70,128,314.96 |
| 税金及附加 | 2,453,889.01 | 1,206,670.13 | 4,488,122.2 | 3,320,047.88 |
| 销售费用 | 24,013,654.17 | 11,506,387 | 42,339,276.45 | 31,680,696.94 |
| 管理费用 | 18,443,798.32 | 8,982,545.32 | 30,717,664.45 | 23,235,208.69 |
| 研发费用 | 9,019,786.95 | 4,851,365.09 | 19,364,701.46 | 14,084,831.12 |
| 财务费用 | 755,213.45 | 287,429.24 | 105,794.49 | 43,252.49 |
| 其中:利息费用 | 153,781.85 | 77,325.02 | 425,520.69 | 344,616.42 |
| 其中:利息收入 | 128,235.65 | 39,425.24 | 337,185.8 | 222,639.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -13,972.6 | -5,260.27 | 24,684.93 | - |
| 加:投资收益 | 432,736.47 | 233,112.64 | 506,028.26 | 336,983.57 |
| 资产处置收益 | -372,512.9 | - | -189,131.82 | -189,131.82 |
| 资产减值损失(新) | -1,000,673.25 | -742,964.69 | -351,435.99 | -549,458.89 |
| 信用减值损失(新) | -96,633.66 | -438,509.63 | 359,981.59 | -768,474.79 |
| 其他收益 | 1,904,354.38 | 726,410.58 | 5,293,408.71 | 4,013,934.77 |
| 四、营业利润 | 43,666,249.61 | 21,935,217.63 | 76,695,512.72 | 55,162,585.71 |
| 加:营业外收入 | 26,054.88 | 25,689.14 | 16,641.44 | 13,892.26 |
| 减:营业外支出 | 81,187.98 | 81,187.98 | 211,404.76 | 189,404.76 |
| 五、利润总额 | 43,611,116.51 | 21,879,718.79 | 76,500,749.4 | 54,987,073.21 |
| 减:所得税费用 | 6,039,467.87 | 2,576,398.84 | 10,231,459.68 | 7,685,522.42 |
| 六、净利润 | 37,571,648.64 | 19,303,319.95 | 66,269,289.72 | 47,301,550.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 37,571,648.64 | 19,303,319.95 | 66,269,289.72 | 47,301,550.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 37,571,648.64 | 19,303,319.95 | 66,269,289.72 | 47,301,550.79 |
| 扣除非经常损益后的净利润 | 36,091,569.86 | 18,640,440.85 | 62,062,040.74 | 44,272,861.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.92 | 0.47 | 1.62 | 1.15 |
| (二)稀释每股收益 | 0.92 | 0.47 | 1.62 | 1.15 |
| 九、综合收益总额 | 37,571,648.64 | 19,303,319.95 | 66,269,289.72 | 47,301,550.79 |
| 归属于母公司股东的综合收益总额 | 37,571,648.64 | 19,303,319.95 | 66,269,289.72 | 47,301,550.79 |
| 公告日期 | 2026-08-20 | 2026-04-21 | 2026-03-20 | 2025-11-10 |
| 审计意见(境内) | | | 标准无保留意见 | |